YORK, U.K. - Abingdon Health plc (AIM: ABDX), a prominent international contract development and manufacturing organization (CDMO), has announced the inauguration of its analytical laboratory situated in Doncaster, operated by its fully-owned subsidiary, Abingdon Analytical Ltd.
The new laboratory is part of the company's strategic expansion to bolster its comprehensive CDMO services, which assist customers in navigating products to market. Abingdon Analytical Ltd will cater to the lateral flow testing market and adjacent sectors, delivering critical services such as product stability testing and sensitivity assessment, all of which are essential for regulatory approvals by authorities like the FDA, EU IVDR, and UKCA.
The opening of this facility follows the company's investment of up to £1 million from recent fundraising efforts. This investment aims to enhance the Group's analytical laboratory services, which in turn supports its regulatory service offerings.
Dr. Chris Hand, Executive Chairman of Abingdon Health, stated that the addition of the analytical laboratory underscores the company's commitment to providing a bridge between its CDMO and regulatory services. The laboratory is designed to generate analytical and product performance data for regulatory technical files, augmenting the broad portfolio of services offered to customers. Dr. Hand also highlighted the announcement of a major contract, which exemplifies the advantages of integrating analytical capabilities into the company's CDMO offerings.
Abingdon Health Group is recognized for its Medtech contract services delivered to an international clientele. The company specializes in lateral flow product development, regulatory support, and large-scale manufacturing. It also provides regulatory services through Compliance Solutions (Life Sciences) and IVDeology, offering a wide range of support to the in vitro diagnostic and medical device industry.
This development is expected to enhance Abingdon Health's position as a comprehensive service provider in the medical device sector. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.